<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872598</url>
  </required_header>
  <id_info>
    <org_study_id>AB09004</org_study_id>
    <nct_id>NCT01872598</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of masitinib for the treatment&#xD;
      of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in&#xD;
      patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase&#xD;
      inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actual standard treatment for mild to moderately severe Alzheimer's dementia includes&#xD;
      acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor&#xD;
      antagonist (memantine for moderate to severe Alzheimer's disease). These medications have&#xD;
      shown to have an effect on some cognitive and non cognitive symptoms of the pathology.&#xD;
      However, their efficacy remains limited and may decrease with time. There is an unmet medical&#xD;
      need in this pathology. Masitinib is a selective tyrosine kinase inhibitor that is thought to&#xD;
      exert a neuroprotective effect through its activity on mast cells and other non-neuronal&#xD;
      cells of the central nervous system, with subsequent modulation of inflammatory and&#xD;
      neurodegenerative processes, as well as possibly disruption of the Aβ signaling cascade via&#xD;
      inhibition of the Fyn signaling pathway. This is a multicenter, double-blind, randomized,&#xD;
      placebo-controlled, parallel-group study of oral masitinib. The objective of this study is to&#xD;
      compare the efficacy and safety of masitinib at various doses versus matched placebo in the&#xD;
      treatment of patients with mild to moderate Alzheimer's Disease. Masitinib will be&#xD;
      administered as add-on therapy in patients who have been treated for a minimum of 6 months&#xD;
      with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine)&#xD;
      and/or memantine. Approximately 675 patients will be randomized into 5 treatment groups. The&#xD;
      co-primary outcome measures are the Alzheimer's Disease Cooperative Study Activities of Daily&#xD;
      Living score (ADCS-ADL), and Alzheimer's Disease Assessment Scale-Cognitive Subscale score&#xD;
      (ADAS-Cog) after 24 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADCS-ADL</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADAS-Cog</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Mini Mental State Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC-plus</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinician's Interview Based Impression of Change-plus (CIBIC-plus)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">721</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Masitinib escalating dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib fixed dose (4.5 mg/kg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib fixed dose (3.0 mg/kg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (escalating dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (fixed dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive fixed dose placebo, given orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <arm_group_label>Masitinib escalating dose</arm_group_label>
    <arm_group_label>Masitinib fixed dose (3.0 mg/kg/day)</arm_group_label>
    <arm_group_label>Masitinib fixed dose (4.5 mg/kg/day)</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (escalating dose)</arm_group_label>
    <arm_group_label>Placebo (fixed dose)</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include:&#xD;
&#xD;
          1. Patient with dementia of Alzheimer's type, according to the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders criteria (DSM-IV)&#xD;
&#xD;
          2. Patient with probable Alzheimer' disease according to the National Institute of&#xD;
             Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and&#xD;
             Related Disorders Association criteria (NINCDS-ADRDA)&#xD;
&#xD;
          3. Patient with MMSE ≥ 12 and ≤ 25 at baseline&#xD;
&#xD;
          4. Patient treated for a minimum of 6 months with a stable dose of cholinesterase&#xD;
             inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose&#xD;
             of memantine for a minimum of 6 months at baseline, with no changes foreseen in&#xD;
             therapy throughout the study.&#xD;
&#xD;
        Exclusion criteria include:&#xD;
&#xD;
          1. Patient with any other cause of dementia not due to Alzheimer's disease.&#xD;
&#xD;
          2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients&#xD;
             with light and mild forms of delusions and delirium will be allowed in the study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno DUBOIS, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpétrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT Sveta Marina</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Stołeczna 7</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Elias</name>
      <address>
        <city>Bucuresti</city>
        <zip>013686</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <disposition_first_submitted>December 7, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 7, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 8, 2020</disposition_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>dementia</keyword>
  <keyword>cognitive disease</keyword>
  <keyword>memory loss</keyword>
  <keyword>cerebrovascular disease</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

